Elekta Appoints New CEO to Drive Growth and Expansion
Leadership Change at Swedish Radiotherapy Giant
Elekta, the Stockholm-based cancer radiotherapy company, has announced the appointment of Jakob Just-Bomholt as its new president and CEO, effective September 1, 2025. This strategic move comes as the company seeks to improve profitability and accelerate growth in key markets.
Just-Bomholt, who previously served as CEO of Danish digital dental scanning firm 3Shape, brings a wealth of experience in strategic leadership and international business expansion. Elekta's founder and chairman, Laurent Leksell, cited Just-Bomholt's ability to drive profitable growth and global expansion as key factors in his selection.
Challenges and Opportunities in the Radiotherapy Market
The appointment comes at a crucial time for Elekta, which faces stiff competition from Siemens Healthineers' Varian in the radiotherapy market. The company is banking on its new Evo radiation therapy machine to strengthen its position, particularly in the United States and China.
While Evo has been successfully launched in Europe, contributing to a 3% global sales growth in the most recent quarter, its U.S. debut has been delayed. Interim CEO Jonas Bolander revealed that Elekta has withdrawn and is in the process of resubmitting its application for FDA clearance, with a greater focus on cybersecurity compliance.
Strategic Focus on Key Markets
Just-Bomholt will be tasked with overseeing Elekta's recovery efforts in the U.S. and China, where sales have been impacted by regulatory challenges and anti-corruption measures, respectively. He will also be responsible for building on the company's momentum in Europe, where the Evo platform has shown promising results.
The new CEO's international experience is expected to play a crucial role in navigating these diverse market conditions and driving Elekta's global expansion strategy. Just-Bomholt will begin the onboarding process in August, working closely with interim CEO Bolander to ensure a smooth transition into his new role.
References
- Elekta appoints Jakob Just-Bomholt as CEO
The company cited Just-Bomholt’s strategic leadership, international experience and ability to drive profitable growth and global expansion as evidence he is the right person for the job.
Explore Further
What specific strategies might Jakob Just-Bomholt implement to accelerate Elekta's growth in the U.S. and China?
How has Elekta's financial performance been impacted in recent years, particularly in key markets?
What is the competitive landscape for Elekta in the radiotherapy sector, including its main competitors like Varian from Siemens Healthineers?
What are the regulatory and anti-corruption challenges that Elekta faces in the U.S. and China, and how might these impact its market strategy?
How does Jakob Just-Bomholt's previous experience at 3Shape provide him with the skills necessary to lead Elekta's international expansion?